Immix Biopharma (IMMX) said Monday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation to NXC-201 as a potential treatment for relapsed/refractory AL amyloidosis.
The company said the designation is intended to accelerate the development and review of promising advanced regenerative medicines that target serious medical conditions.
Immix Biopharma said it is accelerating the enrollment for a phase 1b/2 trial of NXC-201 in AL amyloidosis, expecting to enroll 40 patients. The study's primary endpoints are complete response rate and overall response rate, with an update on the study scheduled for release in the first half of the year, the company added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。